NEWTOWN SQUARE, Pa., Oct. 24, 2017 /PRNewswire/ -- For 20 years, Kibow Biotech has been refining a novel approach to maintaining healthy kidney function "Enteric Dialysis®". Enteric Dialysis® utilizes probiotics (yes, probiotics) to metabolize the waste products (toxins) building up in the bloodstream due to reduced kidney function. Kibow Biotech will be exhibiting for the 13th consecutive year at the annual American Society of Nephrology conference in New Orleans, Louisiana (https://www.asn-online.org/education/kidneyweek/2017/meeting-overview.aspx) from November 2nd to November 4th. Kibow will be exhibiting relevant data showing a correlation between Enteric Dialysis® technology and stabilization of glomerular filtration rate (GFR, the primary measure of kidney function). Chronic Kidney Disease is the 9th leading cause of death in the US, but is also the costliest to treat, consuming close to 1% of the national budget totaling several billion dollars. Renadyl™ is a kidney health supplement, which utilizes Enteric Dialysis® technology to help maintain healthy kidney function. Should the upcoming large-scale Randomized Control Trial (RCT) Health Economics and Outcomes Research (HEOR) clinical trial reaffirm the preliminary data, Renadyl™ is poised to be ideal for securing insurance/Medicare reimbursement. Kibow Biotech is also developing a similar technology targeted towards Gout/Hyperuricemia applications.
If you'll be in New Orleans for the ASN meeting stop by our booth # 1011, we'd be happy to speak with you.
Forward looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities.
About Uremic Toxin Reduction Technology – also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.
Kidney health supplement with a pharma-like validation: Kibow Biotech is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ is not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not show evidence of clinical activity in each and every individual due to various genetic factors or environmental factors including proper storage, and transportation conditions. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Investor & Media Contact:
Terrence O. Tormey
(610) 353-5130 or Email: [email protected]
SOURCE Kibow Biotech